BeiGene, Ltd. Files Q1 2025 10-Q

Ticker: BEIGF · Form: 10-Q · Filed: May 7, 2025 · CIK: 1651308

Beigene, LTD. 10-Q Filing Summary
FieldDetail
CompanyBeigene, LTD. (BEIGF)
Form Type10-Q
Filed DateMay 7, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals, SEC filing

Related Tickers: BGNE

TL;DR

BeiGene's Q1 2025 10-Q is in: financials and operations updated.

AI Summary

BeiGene, Ltd. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business segment performances are presented, reflecting the company's ongoing activities in the pharmaceutical sector.

Why It Matters

This filing provides investors and stakeholders with the latest financial health and operational status of BeiGene, Ltd., crucial for understanding its market position and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, BeiGene faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 7, 2025.

What is the Standard Industrial Classification (SIC) code for BeiGene, Ltd.?

The SIC code for BeiGene, Ltd. is 2834, which corresponds to Pharmaceutical Preparations.

What fiscal year end does BeiGene, Ltd. observe?

BeiGene, Ltd. observes a fiscal year end of December 31.

What is the SEC file number for BeiGene, Ltd.?

The SEC file number for BeiGene, Ltd. is 001-37686.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding BeiGene, Ltd. (BEIGF).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing